SAMS Praises President Biden’s Defense Production Act Order to Address Drug Shortages

WASHINGTON D.C., December 27, 2023 — Securing America’s Medicines and Supply (SAMS), a multi-industry coalition of companies with the mission to strengthen the security of the United States medical supply chain, issued the following statement of endorsement of the Administration’s memorandum related to Sec. 303 of the Defense Production Act (DPA):

“We appreciate the President’s order and his leadership on this important issue for patients and our national security,” said David Sanders, Executive Director of SAMS.

“This is an important first step to address drug shortages and increase America’s domestic manufacturing capabilities for critical medicines.”

“The Administration clearly recognizes the seriousness of ongoing supply chain issues. We encourage them to take additional actions to spur manufacturing in the United States including federal procurement contracts and reimbursement reform. This will require a whole-of-government approach, a ‘CHIPS-style’ package for critical medicines.” 

About Securing America’s Medicines and Supply

Securing America’s Medicines and Supply (SAMS) is a multi-industry coalition of companies with the mission to strengthen the security of the medical supply chain in the United States. SAMS seeks to drive the implementation of legislation and regulation to reward and foster U.S.-made manufacturing of important pharmaceutical products, devices, and supplies. SAMS supports U.S. patients, domestic healthcare security, and U.S. jobs.